<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/">
<title>Health implemenation guidelines &amp; standards</title>
<link href="http://repository.iphce.org/xmlui/handle/123456789/5308" rel="alternate"/>
<subtitle/>
<id>http://repository.iphce.org/xmlui/handle/123456789/5308</id>
<updated>2026-05-20T18:19:45Z</updated>
<dc:date>2026-05-20T18:19:45Z</dc:date>
<entry>
<title>Pharmaceutical products traceability master data guideline, 2nd edition</title>
<link href="http://repository.iphce.org/xmlui/handle/123456789/5373" rel="alternate"/>
<author>
<name>Ethiopian Food and Drug Authority</name>
</author>
<author>
<name/>
</author>
<id>http://repository.iphce.org/xmlui/handle/123456789/5373</id>
<updated>2026-03-04T08:33:28Z</updated>
<published>2022-01-01T00:00:00Z</published>
<summary type="text">Pharmaceutical products traceability master data guideline, 2nd edition
Ethiopian Food and Drug Authority; 
</summary>
<dc:date>2022-01-01T00:00:00Z</dc:date>
</entry>
<entry>
<title>Trends in antimicrobial consumption in Ethiopia: A surveillance  report 2020-2022</title>
<link href="http://repository.iphce.org/xmlui/handle/123456789/5370" rel="alternate"/>
<author>
<name>Ethiopian Food and Drug Authority</name>
</author>
<id>http://repository.iphce.org/xmlui/handle/123456789/5370</id>
<updated>2026-03-04T08:16:19Z</updated>
<published>2022-01-01T00:00:00Z</published>
<summary type="text">Trends in antimicrobial consumption in Ethiopia: A surveillance  report 2020-2022
Ethiopian Food and Drug Authority
Background: Antimicrobial resistance (AMR) poses a severe global health threat, driven by the&#13;
overuse and misuse of antimicrobials across the human, agricultural, and veterinary sectors. To&#13;
combat this, global and national AMR prevention and containment strategies have been&#13;
implemented, necessitating continuous monitoring of antimicrobial consumption (AMC) as an&#13;
integral part of antimicrobial stewardship interventions.
</summary>
<dc:date>2022-01-01T00:00:00Z</dc:date>
</entry>
<entry>
<title>Risk-based guideline for post-marketing quality surveillance of medicines in Ethiopia</title>
<link href="http://repository.iphce.org/xmlui/handle/123456789/5368" rel="alternate"/>
<author>
<name>Ethiopian Food and Drug Authority</name>
</author>
<id>http://repository.iphce.org/xmlui/handle/123456789/5368</id>
<updated>2026-03-04T08:16:41Z</updated>
<published>2024-01-01T00:00:00Z</published>
<summary type="text">Risk-based guideline for post-marketing quality surveillance of medicines in Ethiopia
Ethiopian Food and Drug Authority
Surveillance activities that occur following market approval of a&#13;
medicine, including: maintenance of product authorization and/or&#13;
registration of variations or renewals; regular inspections of&#13;
manufacturers, wholesalers, distributors, and retailers; quality&#13;
control testing; pharmacovigilance; promotion control; public&#13;
reporting of poor-quality products; handling of market complaints;&#13;
&#13;
and removal and disposal of non-compliant products. Post-&#13;
marketing surveillance is typically considered a key regulatory&#13;
&#13;
function and refers to the set of comprehensive quality surveillance&#13;
activities.
</summary>
<dc:date>2024-01-01T00:00:00Z</dc:date>
</entry>
<entry>
<title>Risk-based guideline for post-marketing quality surveillance of  medicines in Ethiopia</title>
<link href="http://repository.iphce.org/xmlui/handle/123456789/5364" rel="alternate"/>
<author>
<name>Ethiopian Food and Drug Authority</name>
</author>
<id>http://repository.iphce.org/xmlui/handle/123456789/5364</id>
<updated>2026-03-04T08:17:31Z</updated>
<published>2020-01-01T00:00:00Z</published>
<summary type="text">Risk-based guideline for post-marketing quality surveillance of  medicines in Ethiopia
Ethiopian Food and Drug Authority
Good quality medicines are essential for efficient disease management. Substandard and falsified&#13;
medicines can cause treatment failure and adverse reactions, increase morbidity and mortality, and&#13;
contribute to the development of drug resistance. Vulnerable populations and patients with&#13;
comorbidities are at particular risk of being harmed from receiving substandard or falsified&#13;
medicines. Poor-quality medicines also increase health care costs to both patients and the health&#13;
system as a whole, wasting resources that could otherwise be used to benefit public health.
</summary>
<dc:date>2020-01-01T00:00:00Z</dc:date>
</entry>
</feed>
